Evidence map›Paper›PMID 39115881›Full record

ArticleFuture oncology (London, England)2024

Abemaciclib for treating patients with HR+/HER2- metastatic breast cancer: a real-world study in France, Italy and Spain.

Isabel Blancas, Jessica Grosjean, Rebecca Pedersini, Carlotta Buzzoni, Ghassan Sleilaty, Alberto Molero, Antonella Tamma, Nadia Chouaki, Manuel Atienza, Anna Emde and 4 more

Abstract readMulticenter Study
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Clinical experience and satisfaction in patients with advanced breast cancer participating in the abemaciclib patient support program in Spain: a prospective observational study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Observational
  2. Review
  3. Review
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Isabel BlancasHospital Universitario Clínico San Cecilio, 18016 Granada, Spain.ORCID 0000-0002-5867-6615
Jessica GrosjeanCentre de Cancérologie Les Dentellières, 59300, Valenciennes, France.
Rebecca PedersiniBreast Unit - Oncologia, ASST Spedali Civili di Brescia, 25213, Brescia, Italy.
Carlotta BuzzoniEli Lilly & Company, 46285, Indianapolis, Indiana, USA.
Ghassan SleilatyEli Lilly & Company, 46285, Indianapolis, Indiana, USA.
Alberto MoleroEli Lilly & Company, 46285, Indianapolis, Indiana, USA.
Antonella TammaEli Lilly & Company, 46285, Indianapolis, Indiana, USA.
Nadia ChouakiEli Lilly & Company, 46285, Indianapolis, Indiana, USA.
Manuel AtienzaEli Lilly & Company, 46285, Indianapolis, Indiana, USA.
Anna EmdeEli Lilly & Company, 46285, Indianapolis, Indiana, USA.
Sara SiddiInstitut de Recerca Sant Joan de Déu (IRSJD), Esplugues de Llobregat, 08950, Barcelona, Spain.
Rodrigo Sanchez BayonaUnidad de Cáncer de Mama y Ginecológico, Hospital Universitario 12 de Octubre, 28041, Madrid, Spain.
Lucia Del MastroUnità Operativa Complessa, Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, 16132, Genova, Italy.
Walid FakhouriEli Lilly & Company, 46285, Indianapolis, Indiana, USA.

Funding

Eli Lilly and Company
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AminopyridinesBenzimidazolesBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesAdultAgedAged, 80 and overFemaleFranceHumansItalyMiddle AgedNeoplasm MetastasisProgression-Free SurvivalReceptors, EstrogenReceptors, ProgesteroneabemaciclibAminopyridinesBenzimidazolesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneabemaciclibHR+/HER2- advanced/metastatic breast cancerreal-worldtreatment outcomestreatment patterns

Identifiers

PMID39115881
PMCPMC11520550

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.